E. D. De Jaeghere, S. Tuyaerts, A. V. Van Nuffel, A. Belmans, K. Bogaerts, R. Baiden-Amissah, P. Vuylsteke, S. Henry, X. Trinh, P. V. van Dam, S. Aspeslagh, A. De Caluwé, E. Naert, D. Lambrechts, A. Hendrix, O. De Wever, K. K. van de Vijver, F. Amant, K. Vandecasteele, H. Denys
{"title":"2022-RA-638-ESGO Pembrolizumab联合多模态免疫调节治疗化疗前宫颈癌、子宫内膜癌和子宫癌:PRIMMO II期试验","authors":"E. D. De Jaeghere, S. Tuyaerts, A. V. Van Nuffel, A. Belmans, K. Bogaerts, R. Baiden-Amissah, P. Vuylsteke, S. Henry, X. Trinh, P. V. van Dam, S. Aspeslagh, A. De Caluwé, E. Naert, D. Lambrechts, A. Hendrix, O. De Wever, K. K. van de Vijver, F. Amant, K. Vandecasteele, H. Denys","doi":"10.1136/ijgc-2022-esgo.401","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial\",\"authors\":\"E. D. De Jaeghere, S. Tuyaerts, A. V. Van Nuffel, A. Belmans, K. Bogaerts, R. Baiden-Amissah, P. Vuylsteke, S. Henry, X. Trinh, P. V. van Dam, S. Aspeslagh, A. De Caluwé, E. Naert, D. Lambrechts, A. Hendrix, O. De Wever, K. K. van de Vijver, F. Amant, K. Vandecasteele, H. Denys\",\"doi\":\"10.1136/ijgc-2022-esgo.401\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":80519,\"journal\":{\"name\":\"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2022-esgo.401\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-esgo.401","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial